Pharmaceutical - Financial, Rare diseases

Filter

Current filters:

FinancialRare diseases

Popular Filters

1 to 25 of 29 results

Another $1 million GSK milestone for Isis Pharma

Another $1 million GSK milestone for Isis Pharma

24-06-2014

USA-based Isis Pharmaceuticals said today that it has earned a $1 million milestone payment from GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR RxPharmaceuticalRare diseasesResearch

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

OxThera gains $10 million investment to continue Phase II trial

16-04-2014

Shareholders of privately-held Swedish biopharmaceutical company OxThera have agreed with a syndicate…

BiopharmaceuticalFinancialKidney diseasesOxabactOxTheraPharmaceuticalPrimary hyperoxaluriaRare diseasesRemi DrollerSweden

Australia to review program for life-saving drugs access

Australia to review program for life-saving drugs access

10-04-2014

The Australian government says that it will review the Life Saving Drugs Program (LSDP) - a move aimed…

Asia-PacificAustraliaFinancialHealthcarePharmaceuticalRare diseases

Promoting competition key to improving patients’ access to high cost medicines, says PHARMAC

Promoting competition key to improving patients’ access to high cost medicines, says PHARMAC

08-04-2014

New Zealand’s Pharmaceutical Management Agency, PHARMAC, has announced its intention to test out a…

Asia-PacificFinancialHealthcareNew ZealandPharmaceuticalRare diseases

ISIS Pharma earns $1 million from GSK for advancing ISIS-TTRRx

03-03-2014

USA-based Isis Pharmaceuticals has earned a $1 million milestone payment from UK pharma giant GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTRRxPharmaceuticalRare diseasesResearch

Sanofi renews alliance with Regulus and ups investment by $10 million

Sanofi renews alliance with Regulus and ups investment by $10 million

05-02-2014

US pharma company Regulus Therapeutics has renewed its strategic alliance with French drug major Sanofi…

FinancialFranceOncologyPharmaceuticalRare diseasesRegulus TherapeuticsResearchSanofiUSA

Aegerion receives US subpoena over USA sales of Juxtapid

Aegerion receives US subpoena over USA sales of Juxtapid

13-01-2014

US biopharma company Aegerion Pharmaceuticals has received a subpoena from the US Department of Justice…

Aegerion PharmaceuticalsFinancialJuxtapidLegalPharmaceuticalRare diseasesUSA

EMA sets greater fee-reduction rates for orphan medicines in 2014

EMA sets greater fee-reduction rates for orphan medicines in 2014

04-12-2013

The European Medicines Agency’s policy on fee reductions for orphan medicinal products has been revised.…

EuropeFinancialPharmaceuticalRare diseases

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

European Medicines Agency simplifies processing of fee reductions for orphan medicines

09-05-2013

The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesRegulation

Orphan diseases' appeal lies in return on investment, says Evaluate

24-04-2013

For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

Merck Serono's EPP funds EspeRare Foundation, which will reposition rimeporide

15-04-2013

Merck Serono, the biotech unit of Germany's Merck KGaA (MRK: DE) has announced the launch of the EspeRare…

BiotechnologyEspeRare FoundationFinancialMerck KGaAMerck SeronoPharmaceuticalRare diseasesResearchrimeporide

Rare diseases research gets 144 million-euro funding from European Commission

01-03-2013

On Rare Disease Day 2013 (February 28), the European Commission announced 144 million euros ($189.5 million)…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesResearch

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus

20-12-2012

Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

EMA updates on fee reduction for SMEs developing orphan drugs in 2013

19-12-2012

The European Medicines Agency's policy on fee reductions for orphan medicinal products is set to continue…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesRegulation

Time for government action on investing in neglected diseases R&D

03-12-2012

A five-year review of global neglected disease R&D funding shows that, despite increased investment of…

FinancialPharmaceuticalRare diseasesResearchTropical diseases

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug

02-11-2012

US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday,…

EuropeFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

$25 million milestone for Protalix following US approval of Elelyso

13-06-2012

Israel-based Protalix BioTherapeutics (TASE:PLX) has received a $25 million milestone payment from global…

ElelysoFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseases

1 to 25 of 29 results

Back to top